Patent Application: Tumor Targeting Methods and Reagents

ChangeBridge: Patent Apps - Pharma (A61K)

Published March 26th, 2026

Detected March 26th, 2026

Summary

The USPTO has published a patent application (US20260083867A1) detailing methods and reagents for tumor targeting in cancer treatment. The application, filed on November 21, 2025, describes a combination therapeutic approach using agents with different biodistributions to enhance efficacy and reduce toxicity.

View original document View source feed page

What changed

This document is a published patent application from the USPTO for a novel method and reagents for tumor targeting in cancer treatment. The invention involves administering two agents, each with a targeting component coupled to a therapeutic component, where the targeting components have distinct biodistributions or pharmacokinetics. This approach aims to improve treatment efficacy and reduce toxicity.

While patent applications do not impose direct regulatory obligations on companies, they signal potential future intellectual property and market exclusivity in specific therapeutic areas. Companies involved in oncology drug development, particularly those exploring combination therapies or novel targeting mechanisms, should be aware of this filing. It may influence R&D strategies and competitive landscapes in the pharmaceutical sector.

Source document (simplified)

← USPTO Patent Applications

METHODS AND REAGENTS FOR TUMOR TARGETING WITH GREATER EFFICACY AND LESS TOXICITY

Application US20260083867A1 Kind: A1 Mar 26, 2026

Inventors

Neil H. BANDER

Abstract

The present invention relates to a method for treating cancer. This method involves providing a first agent comprising a first targeting component coupled to a first cancer therapeutic component and providing a second agent comprising a second targeting component coupled to a second cancer therapeutic component. The first and second targeting components have different biodistributions and/or pharmacokinetics. The first and second agents are administered to a subject having cancer to treat the cancer. Also disclosed is a combination therapeutic comprising the first and second agents.